Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Berry

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Breast Cancer Research : BCR|November 30, 2006
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342Lyndsay N Harris, Gloria Broadwater, Nancy U Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromesLanlan Shen, Hagop Kantarjian, Yi Guo, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
The Lancet. Oncology|September 16, 2021
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgeryJoe Y Chang, Reza J Mehran, Lei Feng, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Breast Cancer Research : BCR|November 30, 2006
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342Lyndsay N Harris, Gloria Broadwater, Nancy U Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committeeLesley Seymour, S Percy Ivy, Daniel Sargent, et al.
Expert Review of Neurotherapeutics|December 27, 2014
Charting a path toward combination therapy for Alzheimer's diseaseDiane Stephenson, Dan Perry, Cynthia Bens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromesLanlan Shen, Hagop Kantarjian, Yi Guo, et al.
Breast Cancer Research and Treatment|June 15, 2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806Mercedes Rincon, Gloria Broadwater, Lyndsay Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
The Lancet. Oncology|September 16, 2021
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgeryJoe Y Chang, Reza J Mehran, Lei Feng, et al.
Pageof 6